LOW-DOSE VALGANCICLOVIR FOR 3 MONTHS PREVENTS CYTOMEGALOVIRUS (CMV) DISEASE IN RENAL AND PANCREAS TRANSPLANT RECIPIENTS, INCLUDING RECIPIENTS AT HIGH-RISK FOR CMV DISEASE.

MLA

Weng, Francis L., et al. “Low-Dose Valganciclovir for 3 Months Prevents Cytomegalovirus (Cmv) Disease in Renal and Pancreas Transplant Recipients, Including Recipients at High-Risk for Cmv Disease.” Transplantation, vol. 82, July 2006, pp. 585–86. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=114954487&authtype=sso&custid=ns315887.

APA

Weng, F. L., Patel, A. M., Wanchoo, R., Brahmbhatt, Y., Ribeiro, K., Uknis, M. E., Mulgaonkar, S., & Mathis, A. S. (2006). Low-Dose Valganciclovir for 3 Months Prevents Cytomegalovirus (Cmv) Disease in Renal and Pancreas Transplant Recipients, Including Recipients at High-Risk for Cmv Disease. Transplantation, 82, 585–586.

Chicago

Weng, Francis L, Anup M Patel, Rimda Wanchoo, Yasmin Brahmbhatt, Kezia Ribeiro, Marc E Uknis, Shamkant Mulgaonkar, and A Scott Mathis. 2006. “Low-Dose Valganciclovir for 3 Months Prevents Cytomegalovirus (Cmv) Disease in Renal and Pancreas Transplant Recipients, Including Recipients at High-Risk for Cmv Disease.” Transplantation 82 (July): 585–86. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=114954487&authtype=sso&custid=ns315887.